Peripheral lymphoid cells, from 12 cases of acute infectious mononucleosis (IM), were tested in a micro chromium-51 release assay for cytotoxic activity against a variety of cell lines that did or did not carry the Epstein-Barr virus (EBV) genome. Unfractionated lymphocytes from these patients were cytotoxic to both types of cell lines, as were lymphocytes from healthy individuals. If, however, lymphocytes bearing complement receptors were removed, the residual IM lymphocyte fraction was specifically cytotoxic for EBV-genome-carrying cell lines. The residual lymphocyte fraction in normal donors had no such effect. Heterophile-positive IM is caused by EBV, and these results indicate that, during the acute phase of this disease, patients harbor killer cells, probably T cells, which specifically kill EBV-genome-carrying B cells in vitro. No such specificity for EBV-genome-positive target cells was found in normal lymphocytes stimulated in vitro with autologous EBV-genome-positive lymphoblastoid cells. Such stimulated cells were highly cytotoxic to both genome-positive and negative lines after removal of complement receptor-positive lymphocytes.
The Epstein-Barr virus (EBV) has been regularly associated with three human diseases; infectious mononucleosis (IM) (1), Burkitt's lymphoma (BL) (2) , and nasopharyngeal carcinoma (2) . The etiologic role of this virus is clearly established in IM, whereas, it remains suggestive but not proven in BL and nasopharyngeal carcinoma. IM is characterized by an intensive lymphoproliferation which, although it sometimes resembles the acute phase of leukemia, always is self-limiting and benign in character. This self-limitation in viw is in contrast to the capacity of the patient's lymphocytes to proliferate indefinitely in vitro as continuous cell lines with surface characteristics typical for bone-marrow derived (B) lymphocytes (2) . Such cell lines carry the EBV genome, as shown by nucleic acid hybridization or the presence of the EBV-associated nuclear antigen (EBNA) (2, 3) . It would be essential to understand what mechanisms protect the IM patients from continuous lymphoproliferation.
Recent investigations have shown that a high proportion of the blast-transformed cells found in the peripheral blood of IM patients are thymus-derived (T) lymphocytes (4-7).
As T lymphocytes are known to be the major defense mechanism in many viral infections (8) , we In our first experiments we were not able to demonstrate any specificity of IM lymphocytes for EBV-genome-carrying cells, due mainly to a high background cytotoxicity of normal lymphocytes against both EBV genome positive and negative lines. Jondal and Pross have since shown that the "nonspecific" cytotoxicity of normal lymphocytes against EBV-genome-positive and negative cell lines, and also against lines of nonlymphoid origin, can be largely abolished by removing cells with complement (C') receptors from the lymphocyte population (9) .
By removing these "nonspecifically" cytotoxic lymphocytes in the IM system it has now been possible to demonstrate killer cells specific for EBV-carrying target cells. (10, 11) in all cases. Seven of the patients had a Paul Bunnell and Davidson titer over 1/300, the others had titers ranging from 1/10 to 1/40. All patients were hospitalized cases, and were tested within 14 days after admission. Two cases were studied twice with 1 week's interval.
MATERIALS AND METHODS

IM
Lymphocytes from 3 EBV-seropositive normal individuals (ES, MJ, and NG) were used as controls. ES was used as reference control in seven out of eight experiments.
Lymphocyte Purification. Lymphocytes were isolated on Ficoll-Isopaque gradients (12) , washed three to four times to remove thrombocytes, and then treated with carbonyl iron and magnetism (13) . Usually 1/4 of the lymphocytes were kept without further purification and the rest treated to remove C' receptor positive cells by rosette sedimentation, as earlier described (13 Chromium-S1 Release Cytotoxicity Test. The assay was carried out as described earlier (14) with some slight modifications. The medium used was RPMI 1640 supplemented with 5 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (Hepes) buffer + 20% heat-inactivated fetal calf serum.
The assay was done in a total volume of 0.14 ml in V-shaped 1622 KAPLAN , whether C' receptor-positive lymphocytes were removed or not. In contrast, most toxicity of the normal lymphocytes disappeared after removal of C' receptor-positive cells. The EBV-genomenegative K562 was highly sensitive to the normal and to most IM lymphocytes, but little or no cytotoxic activity remained after depletion of the C' receptor-bearing lymphocytes. There was a clear dose-response relationship for the cytotoxicity of fractionated IM lymphocytes. The magnitude of this cytotoxic effect varied between patients.
Figs. 1 and 2 summarize the results with lymphocytes from all 12 IM patients against several EBV-genome-positive and negative lines, with the higher effector cell number (3 X 106).
A complete set of data is given for target cells KAPLAN and K562, in Table 2 . These two cell lines were used as reference EBV-genome-positive and negative target cells respectively, in all experiments except no. 4 involving IM patients 4 and 5. Fig. 1 shows that EBV-genome-positive lines were sensitive to IM lymphocytes and that this cytotoxic effect did not disappear after removal of the "nonspecifically" cytotoxic cells. The GC-BJAB was the one exception, since it behaved like its genome-negative "mother" cell, BJAB. There was a clear difference in cytotoxic activity between the lymphocytes of different IM patients and possibly also some difference in the sensitivity of the different lines. ES-W-1 and ES-2 appeared to be fairly insensitive, but this might have been due to the fact that they were only tested against IM lymphocytes with a comparatively low cytotoxic activity. The average effect of control lymphocytes from normal donors is given for each target cell below the histogram. Most of this cytotoxic effect disappeared after fractionation. When unfractionated IM lymphocytes were cytotoxic against EBV-genome-nega- Table 1. fresh IM lymphocytes. This cytotoxic activity did not disappear upon removal of C' receptor-bearing cells, however, neither againstEBV-genome-positive nor negative lines (Fig. 3) .
DISCUSSION
Earlier reports (4) (5) (6) (7) have demonstrated that a high proportion of the blast-transformed cells in the peripheral blood of IM patients are T-cell-derived. We and others have speculated that these T cells might be instrumental in bringing about the self-limitation of the disease (14, 7) . Since EBV is known to be the cause of IM our approach to this problem was to investigate whether IM blood contained effector cells with cytotoxic specificity for EBV-genome-carrying target cells. of different cell lines in a nonspecific manner. It was, therefore, a logical step to remove these cells in order to investigate whether a specificity directed against EBV-genome-positive lines was hidden in the rest of the lymphocyte population. Thus, a specific killer cell population was found.
Although this study does not formally prove that the cytotoxicity directed against the EBV-genome-positive lines is a Tcell function, this conclusion is most probable. It is fair to assume that the cytotoxicity represents T-cell-mediated immunity directed against EBV-infected cells. It is interesting to note that this reactivity is directed against EBV-genomecarrying lines from both normal donors and from patients with BL or IM. This finding could be clinically important, as it has been shown that cell-mediated immunity can, under certain conditions, be transferred between individuals with so called transfer factor (23) . If 
